Myelodysplastic Syndromes (MDS)

Mariam Nawas, MD

Institution
University of Chicago
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)

Michael Drazer, MD, PhD

Institution
University of Chicago
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
Michael Drazer, MD, PhD, is a hematologist/oncologist and geneticist specializing in the care of people with blood disorders, blood cancers, hereditary blood disorders, and hereditary cancer syndromes. He runs one of the only clinics in the world focused on the care of people with hereditary blood cancer syndromes. Dr. Drazer's laboratory research focuses on determining the mechanisms that drive hereditary blood and cancer syndromes, with a particular emphasis on developing "high fidelity" cellular and mouse models of these disorders. He is also heavily involved in the discovery of novel

Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial

Background: The preplanned interim analysis of the COMMANDS trial showed greater efficacy of luspatercept than

Subscribe to Myelodysplastic Syndromes (MDS)

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.